StreetInsider.com News Articles

argenx to Report Half Year 2026 Financial Results and Second Quarter Business Update on July 23, 2026

Thu, 16 Jul 2026 01:00:00 -0400

July 16, 2026

Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that it will host a conference call and audio webcast on Thursday, July 23, 2026 at 2:30 p.m. CET (8:30 a.m. ET) to discuss its half year 2026 financial results and provide a second quarter business update.

A webcast of the live call may be accessed on the Investors section of the argenx website at argenx.com/investors. A replay of the webcast will be available

argenx to Report Half Year 2026 Financial Results and Second Quarter Business Update on July 23, 2026

Thu, 16 Jul 2026 01:00:00 -0400

A webcast of the live call may be accessed on the Investors section of the argenx website at argenx.com/investors. A replay of the webcast will be available

argenx to Report Half Year 2026 Financial Results and Second Quarter Business Update on July 23, 2026

Thu, 16 Jul 2026 01:00:00 -0400

A webcast of the live call may be accessed on the Investors section of the argenx website at argenx.com/investors. A replay of the webcast will be available

argenx to Report Half Year 2026 Financial Results and Second Quarter Business Update on July 23, 2026

Thu, 16 Jul 2026 01:00:00 -0400

A webcast of the live call may be accessed on the Investors section of the argenx website at argenx.com/investors. A replay of the webcast will be available

argenx to Report Half Year 2026 Financial Results and Second Quarter Business Update on July 23, 2026

Thu, 16 Jul 2026 01:00:00 -0400

A webcast of the live call may be accessed on the Investors section of the argenx website at argenx.com/investors. A replay of the webcast will be available

argenx to Report Half Year 2026 Financial Results and Second Quarter Business Update on July 23, 2026

Thu, 16 Jul 2026 01:00:00 -0400

A webcast of the live call may be accessed on the Investors section of the argenx website at argenx.com/investors. A replay of the webcast will be available

argenx to Report Half Year 2026 Financial Results and Second Quarter Business Update on July 23, 2026

Thu, 16 Jul 2026 01:00:00 -0400

A webcast of the live call may be accessed on the Investors section of the argenx website at argenx.com/investors. A replay of the webcast will be available

argenx to Report Half Year 2026 Financial Results and Second Quarter Business Update on July 23, 2026

Thu, 16 Jul 2026 01:00:00 -0400

A webcast of the live call may be accessed on the Investors section of the argenx website at argenx.com/investors. A replay of the webcast will be available

argenx SE (ARGX) PT Raised to $945 at RBC Capital

Tue, 07 Jul 2026 07:59:16 -0400

RBC Capital analyst Luca Issi raised the price target on argenx SE (NASDAQ: ARGX) to $945.00 (from $880.00) while maintaining a Outperform rating.

argenx SE (ARGX:BB) (ARGX) PT Raised to EUR900 at Deutsche Bank

Fri, 03 Jul 2026 03:03:34 -0400

Deutsche Bank analyst Emmanuel Papadakis raised the price target on argenx SE (ARGX:BB) (NASDAQ: ARGX) to EUR900.00 (from EUR750.00) while maintaining a Buy rating.

The analyst comments: “Argenx has been a unique, disruptive European innovation story. Here, we here undertake a detailed preview of the company’s two key H2 trial events (Vyvgart in myositis, empasiprubart in MMN) along with those due beyond, plus a review of recent developments in the competitive landscape (FcRn space and beyond, both direct and x-reads…) and our takes from recent events (including scientific updates plus the recent myositis investor event). We also publish our updated and

argenx SE (ARGX:BB) (ARGX) PT Raised to EUR900 at Deutsche Bank

Fri, 03 Jul 2026 03:03:34 -0400

Deutsche Bank analyst Emmanuel Papadakis raised the price target on argenx SE (ARGX:BB) (NASDAQ: ARGX) to EUR900.00 (from EUR750.00) while maintaining a Buy rating.

argenx SE (ARGX:BB) (ARGX) PT Raised to EUR900 at Deutsche Bank

Fri, 03 Jul 2026 03:03:34 -0400

Deutsche Bank analyst Emmanuel Papadakis raised the price target on argenx SE (ARGX:BB) (NASDAQ: ARGX) to EUR900.00 (from EUR750.00) while maintaining a Buy rating.

argenx SE (ARGX:BB) (ARGX) PT Raised to EUR900 at Deutsche Bank

Fri, 03 Jul 2026 03:03:34 -0400

Deutsche Bank analyst Emmanuel Papadakis raised the price target on argenx SE (ARGX:BB) (NASDAQ: ARGX) to EUR900.00 (from EUR750.00) while maintaining a Buy rating.

argenx SE (ARGX:BB) (ARGX) PT Raised to EUR900 at Deutsche Bank

Fri, 03 Jul 2026 03:03:34 -0400

Deutsche Bank analyst Emmanuel Papadakis raised the price target on argenx SE (ARGX:BB) (NASDAQ: ARGX) to EUR900.00 (from EUR750.00) while maintaining a Buy rating.

argenx SE (ARGX:BB) (ARGX) PT Raised to EUR900 at Deutsche Bank

Fri, 03 Jul 2026 03:03:34 -0400

Deutsche Bank analyst Emmanuel Papadakis raised the price target on argenx SE (ARGX:BB) (NASDAQ: ARGX) to EUR900.00 (from EUR750.00) while maintaining a Buy rating.

argenx SE (ARGX) PT Raised to $1,088 at BofA Securities

Wed, 01 Jul 2026 16:35:44 -0400

BofA Securities analyst Tazeen Ahmad raised the price target on argenx SE (NASDAQ: ARGX) to $1,088.00 (from $1,016.00) while maintaining a Buy rating.

The analyst comments "Following ARGX’s recent Myositis Investor Event (see our June 24 note), we add standalone value for immune-mediated necrotizing myopathy (INM) to our model. The new disclosure that the INM subgroup was the key driver of the clinically meaningful responses in phase 2 (>60% of patients enrolled) and KOL feedback underscoring the high unmet need and clear biological rationale for Vyvgart in INM gives us increased confidence in the potential for a positive phase 3 readout

argenx SE (ARGX) PT Raised to $1,088 at BofA Securities

Wed, 01 Jul 2026 16:35:44 -0400

BofA Securities analyst Tazeen Ahmad raised the price target on argenx SE (NASDAQ: ARGX) to $1,088.00 (from $1,016.00) while maintaining a Buy rating.

Wells Fargo Lists 8 Tactical Ideas for Q3 2026

Wed, 01 Jul 2026 06:22:32 -0400